DIGITAL THERAPEUTICS FOR ALZHEIMER’S DISEASE AND DEMENTIA

Our mission is to restore patients’ independence and quality of life by detecting and treating Dementia with digital technology

DEMENTIA IS PROJECTED TO BECOME A LEADING CAUSE OF DEATH AND HEALTHCARE COSTS

Brain+ is addressing one of the largest healthcare challenges of our time, namely dementia. Currently, 1 in 3 seniors die with/of dementia in the US and globally 50 million people are diagnosed with dementia – and unfortunately, this figure is expected to more than triple to 152 million people by 2050. As we generally live longer and the prevention and treatment of the most common causes of death such as cancer and heart disease are getting more efficient, dementia is expected to become a leading cause of death by 2030 and is already the leading cause of death for women in the UK.

Dementia puts an enormous emotional burden on the patients and their loved ones as cognitive abilities deteriorate, behaviours change, and independence is lost. It is also a massive and increasing financial burden on society and our health care systems with an accumulated global cost upwards of 1 trillion USD globally today and expected to double to 2 trillion USD within decades, and eventually expected to eclipse the cost of cancer and heart disease.

TREATING DEMENTIA WITH DIGITAL THERAPEUTICS

Despite massive investments in research for treatments of dementia, there is still a high need for innovative and effective treatments for dementia.

The good news is that Brain+ is leveraging new and innovative methods to create ground- breaking new treatments and provide these to patients in the shape of digital therapeutics. So far, initial trials indicate positive effects of these new methods for the treatment of cognitive decline in dementia.

WHAT ARE DIGITAL THERAPEUTICS?

“Digital Therapeutics” (also referred to as DTX or Digital Medicine) is a term for digital treatments that deliver scientifically validated positive outcomes for a wide range of diseases, and often for the same medical endpoints as classical drugs.

In this sense, DTX offers a new and rapidly growing approach to the way health care systems identify and treat diseases, and could offer new solutions in areas with large unmet clinical needs.

DTX delivers treatments in purely digital formats, like software and apps on people’s smart devices. These treatments can have health effects similar to that of traditional, chemically-based medicine and undergo similar clinical trials and regulatory approval. This allows for new and unique treatment opportunities, that can be used either as a complementary treatment to classic medicine or as a standalone solution in areas where traditional drugs do not offer a solution.

Cognitive Stimulation Therapy (CST)
for treatment of Dementia

In 2020, Brain+ partnered with researchers and clinicians in Denmark to digitalize an evidenced based manual therapy, CST, targeting people with mild to moderate dementia.

Cognitive Stimulation Therapy uses psychosocial interaction to stimulate cognition and create new associations via existing memories, stimulation of memory networks, imagination for people with mild to moderate Alzheimer’s. It also works to increase the quality of the patient’s interaction with their caregivers, as it facilitates a structured way to engage socially. It provides orientation to make the participants feel safe and self-confident, stimulating cognition through multiple sensory activation, and using reminiscence as an aid to the here-and-now.

Brain+ digitalized version of the CST product is designed to be used at home or in a clinic. It is currently undergoing clinical trial validation to prepare for commercialization.

PRODUCTS

Your digital CST Assistant

The digital CST assistant gives you access to 24 prepared Cognitive Stimulation Therapy sessions (CST), ready for use in a CST group setting.

The digital CST assistant creates the foundation for meaningful conversations based on the evidence-based group therapeutic method of CST.

The Digital CST assistant is currently available in Danish. More language versions to follow.

LEARN MORE (Danish Content)

NEWS

Leading dementia researcher joins Brain+
Brain+ adds new clinical and development competences To accelerate and support market access of its digital dementia product portfolio Rising star clinical dementia researcher to join the company in a new position as Clinical Director […]
CST Therapist Companion advancing
Brain+ further advances its first digital dementia product, Cognitive Stimulation Therapy (CST) – Therapist Companion Commercial launch in Denmark will be November 1, 2022 Adaptation of a UK product version for the United Kingdom starts […]
Brain+ begins early activity and brand building in the US
Brain+ begins early activity and brand building in the US The United States (US) is a key future market for Brain+, and early brand building and exploration is now ongoing Brain+ has been selected and […]
First milestone met
Brain+ meets milestone with Rox Health (Roche Germany) Rox Health has approved the German version of Brain+’s first digital dementia product, CST-Therapist Companion, for commercial launch. Meeting this milestone unlocks access for Brain+ to additional […]
New Research report values Brain+
New research report values Brain+ at DKK 4.1 per share in the base case, and DKK 6.4 in the bull case. The research report concludes that “Brain+ is in a strong position to grow towards […]
Accelerated launch Q2 2023
Brain+ partners with German medical distributor Advances launch of its first CST dementia product in Germany to Q2 2023 Through Coopmed, Brain+ will be represented by experienced and local medical sales managers in […]
Brain+’ new product for dementia launching Q4 2022
Brain+’ new product for dementia launching Q4 2022 Digital “CST–Therapist Companion” is launching one year ahead of plan The Brain+ “CST-Therapist Companion” is a new digital product to deliver Cognitive Stimulation Therapy […]
Growing interest in DTx from big pharma
Brain+ is experiencing growing interest from big pharma in its Digital Therapeutics solutions for dementia. Brain+ is a first mover in the field of Digital Therapeutics (DTx) solutions to treat Alzheimer’s Disease (AD) and other […]
Common Nordic digital health evaluation framework launched
Common Nordic digital health evaluation framework launched Digital Therapeutics (DTx) is a growing trend and is increasingly a recognized market providing an important supplement to the established trillion USD pharmaceutical market (traditional medicine). The DTx […]